Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
about
Modeling the within-host dynamics of HIV infectionKorean red ginseng slows depletion of CD4 T cells in human immunodeficiency virus type 1-infected patientsThe human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.Acetylation of HIV-1 integrase by p300 regulates viral integration.Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionResidual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cellsDual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissueExpression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acidT cell-specific siRNA delivery suppresses HIV-1 infection in humanized miceLatent reservoirs of HIV: obstacles to the eradication of virusTargeted DNA mutagenesis for the cure of chronic viral infectionsA stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected childrenPractical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIVInhibition of HIV-1 replication in primary human monocytes by the IkappaB-alphaS32/36A repressor of NF-kappaBHuman immunodeficiency virus type 1 (HIV-1) proviral DNA load in purified CD4+ cells by LightCycler real-time PCR.Characterization of two candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency.Different patterns of HIV-1 DNA after therapy discontinuation.Latency: the hidden HIV-1 challenge.Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual questionTargeting the latent reservoir to achieve functional HIV cureChallenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV ReservoirsImpact of Chromatin on HIV ReplicationManipulation of the host protein acetylation network by human immunodeficiency virus type 1How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?Redefining the viral reservoirs that prevent HIV-1 eradicationStudies of retroviral infection in humanized miceHIV-1 eradication strategies: design and assessmentCombinatorial RNA-based gene therapy for the treatment of HIV/AIDSEmerging strategies to deplete the HIV reservoirHuman immunodeficiency virus (HIV)-1 integration sites in viral latencyTargeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latencyMulti-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque ControllersPersistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplantHistone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytesTargeting the Brain Reservoirs: Toward an HIV CureAre T cells the only HIV-1 reservoir?Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatmentDepletion of latent HIV-1 infection in vivo: a proof-of-concept studyERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaBMacrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans
P2860
Q21245370-7578465C-FD48-4B6D-A943-7DA88F896562Q24521463-A9647295-D19D-4100-AF9C-8082DFCA02E0Q24525309-BA97AC3C-3C34-4460-9BD4-533203C3C865Q24532024-7E9D4339-1EC0-4C05-A960-52A8530EE325Q24536249-976D6B86-2C82-46E0-8E49-8A9100B41B55Q24548940-47700EF7-2BF9-4562-B5A8-71588B91D062Q24562082-7DBF975B-AF34-4D64-AC28-38D77749015AQ24596282-4D53D05C-7EAC-495B-ACFC-E9EB0B910103Q24603574-0306DA91-F7C1-4533-9715-536F2FD3F0B4Q24615570-80526A7F-8920-4BB5-8467-C1F1F3F628B7Q24620150-6B3D4E70-F0BE-4679-A36B-EB3EEB688C2BQ24620746-C45E91A7-CBCB-43F9-B72C-DB3CD5D9AAD6Q24654112-F17D6B29-BB68-4356-84A7-6CEB7CA228ECQ24802730-B0F10BCA-5B89-4CC7-93E9-EFF73930BCE9Q24811629-5E9F58AC-2747-4291-871A-4B71FFE1EB60Q24815984-6EA862C3-CA31-4A0F-9FB7-12806419118FQ24816681-94422E43-CC4A-4603-BADB-CAE7A688EAC9Q25255905-2ADBC142-1918-4EAA-BC23-13F7E6CE8D98Q26741384-49573BC1-FD10-4CDA-91B2-DCF9E34CFB1BQ26745923-CD358720-DAAE-4529-A40A-B2A3799E8B65Q26781511-B244C591-A724-44DF-9210-B07237DA28BFQ26782046-D70160E9-3CED-47BD-B53E-549E6125CF6EQ26795463-66A3E1FA-8E1F-4E13-9632-89F5EEF75138Q26822422-BC8713CA-EF25-47E1-8545-74CC27ECD015Q26827255-9FDC65D7-5478-4DD7-9032-FD12184BE094Q26849806-65DF89FF-0B71-4611-B70B-876047ABE540Q26864933-CC240866-2DFB-41E8-974E-B9ECCAAE54C5Q26866145-F8643D04-7AAD-4705-97C8-E0C4053973B1Q27023877-13E8407E-B2A7-4FE0-9FC0-775561E31F04Q27026246-9608CD76-D3C8-46CA-822E-DEF4CA2A0AA6Q27026631-74B53381-103E-4535-9ECA-1A96CF081727Q27312050-28E97314-FA77-429B-A36F-39298287E449Q27323780-486AADFA-9C89-4578-8E3F-A2BAC81A6D38Q27324527-FE0F29DC-80D8-407C-8C6C-FFDEA2B82C5FQ28075694-1F720D29-5E35-46B8-84AC-C5FCCC6E9E86Q28078850-B0F5397E-01B3-4855-893C-E78536E5C3BDQ28087526-BB5D8AF2-5E04-453C-B4CD-EDA667FD19DCQ28111910-345CF8C3-84C1-4B6F-B88B-57E1B204E661Q28144441-784E6DC2-1AF2-4C7E-925B-4F284A062684Q28345408-452FD7B0-9DA3-473C-979E-990383462277
P2860
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Presence of an inducible HIV-1 ...... active antiretroviral therapy
@ast
Presence of an inducible HIV-1 ...... active antiretroviral therapy
@en
type
label
Presence of an inducible HIV-1 ...... active antiretroviral therapy
@ast
Presence of an inducible HIV-1 ...... active antiretroviral therapy
@en
prefLabel
Presence of an inducible HIV-1 ...... active antiretroviral therapy
@ast
Presence of an inducible HIV-1 ...... active antiretroviral therapy
@en
P2093
P2860
P3181
P356
P1476
Presence of an inducible HIV-1 ...... active antiretroviral therapy
@en
P2093
P2860
P304
P3181
P356
10.1073/PNAS.94.24.13193
P407
P577
1997-11-25T00:00:00Z